Loading...
Immunotherapies & Innovations for Infectious Diseases Congress 2021

November 15 & 16 LYON, France

News Twitter

Program

Day 1

Monday, 15th November 2021

8h00

Registration & welcome coffee

8h45

Welcome Address

9h00

Keynote lectures

The world needs a new international system for pandemic preparedness and response
UNAIDS Michel Kazatchkine

Michel Kazatchkine
Special Advisor
Joint United Nations Program on AIDS (UNAIDS)
Affiliate / course director
Global Health Center, the Graduate Institute of International and Development Studies, Geneva

Boerhinger Ingelheim, France Egbert Mundt

Egbert Mundt
Head New Biological Entities
Boerhinger Ingelheim, France

10h00

Coffee Break - Exhibition Hall - B2B Meetings

10h30

Track 1 : Anti-infectious approaches: new trends and challenges

Session 1

Aix Marseille Université, France Xavier de Lamballerie

Xavier de Lamballerie
Professor
Aix Marseille Université, France

Trained immunity: a memory for innate host defense
Radboud University Medical Center Xavier de Lamballerie

Mihai Netea
Professor & Head of the division of Experimental Medicine
Department of Internal Medicine, Radboud University Medical Center, The Netherlands

CD40 agonists boost IFN-induced signaling pathway and subsequent anti-HBV response in vitro and in vivo
Evotec Antoine Alam

Antoine Alam
Antiviral Reaserch Head
Evotec, France

Track 2 : Prediction of future infectious outbreaks

Pasteur Institute Sylvie van Der Werf

Sylvie van Der Werf
Head of Molecular Genetics of RNA viruses
Pasteur Institute, France

Risk and randomness – epidemiological surveillance for future outbreaks
Ausvet Angus Cameron

Angus Cameron
Executive Consultant
Ausvet, France

EQUIPEX + INFECTIOTRON: Integrative and multidisciplinary tools for the study of infectious diseases from the wild to the lab
INRAE Fabienne Archer

Fabienne Archer
Research director
INRAE
Director
Viral Infections and Comparative Pathology laboratory IVPC, Lyon1, INRAE, EPHE, France

CNRS Fabrice Vavre

Fabrice Vavre
Research director
CNRS
Director
Laboratory of Biometry and Evolutionary Biology, Lyon 1, CNRS, VetAgro Sup, France

11h45

Breakthrough innovation Session

A non-adjuvanted vaccine platform for vaccines
Vaxinano Didier Betbeder

Didier Betbeder
CEO & CSO
Vaxinano, France

Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization using a versatile adenovirus-inspired multimerization platform
IBS/CNRS Pascal Fender

Pascal Fender
Research Director, Team leader
IBS/CNRS, France

OVX836, NP-based universal influenza vaccine candidate: results of phase 2A clinical trial
Osivax Alexandre Le Vert

Alexandre Le Vert
CEO & Co-founder
Osivax, France

12h00

Lunch - Poster Presentation - B2B Meetings 5 slots - Exhibition Hall

14h00

Track 1 : Anti-infectious approaches: new trends and challenges

Session 2

Hôpital Bicêtre AP-HP Thierry Naas

Thierry Naas
Co-director
CNR antibiorésistance, Hôpital Bicêtre AP-HP, France

Phage therapy, an alternative approach to antibiotics ?
Bioaster Gilles Courtemanche

Gilles Courtemanche
Antimicrobials Program Head
Bioaster

BV100 and BVL-GSK098, two clinical stage molecules to fight multidrug resistant bacterial infections
BioVersys Michel Pieren

Michel Pieren
Clinical Project Manager
BioVersys, Switzerland

Track 3 : New tools for monitoring diagnosis and pronostics

Scaling up the responses to infectious diseases’ challenges ?
IARC BIOBANK Zisis Kozlakidis

Zisis Kozlakidis
Director
IARC BIOBANK, France

UCL Olivier Vandenberg

Olivier Vandenberg
Innovation and Business Development Unit, LHUB - ULB
Pôle Hospitalier Universitaire de Bruxelles (PHUB), Belgium
Honorary Senior Research Associate, Division of Infection & Immunity
UCL, London, UK

Current trends in microbiological diagnostics
bioMérieux Alex van Belkum

Alex van Belkum
Scientific Director of Microbiology
bioMérieux, France

Pain points for discoveries in infectious diseases : looking back to the future
Beckman Coulter Anis Larbi

Anis Larbi
Field Marketing Manager, Western Europe
Beckman Coulter, France

16h00

Coffee Break - Exhibition Hall - B2B Meetings

16h30

Track 1 : Anti-infectious approaches: new trends and challenges

Session 3

Enlivex Oren Hershkovitz

Oren Hershkovitz
CEO
Enlivex, Israel

A novel therapeutic approach for the treatment of shiga-toxin producing E. coli infections.
Eligo Bioscience Edith Hessel

Edith Hessel
Chief Scientific Officer
Eligo Bioscience, France

Enterome Christophe Bonny

Christophe Bonny
Chief Scientific Officer
Enterome, France

Breakthrough innovation Session

Development of specific polyclonal F(ab’)2 immunoglobulin fragments against SARS-CoV-2
Fab'entech Cecile Herbreteau

Cecile Herbreteau
Head of R&D Department
Fab'entech, France

An innovative repurposing strategy to rapidly respond to (re)emerging infectious threats
Signia Therapeutics Thomas Lahlali

Thomas Lahlali
R&D Project Leader
Signia Therapeutics, France

Green Tropism Delphine Garsuault

Delphine Garsuault
Research Engineer
Green Tropism, France

Targeting the reservoir of latent HIV and Epstein-Barr virus for AIDS functional cure and prevention of post-transplantation lymphoproliferative disorders.
Hormae Pharma Patrice André

Patrice André
CEO
Hormae Pharma, France

Novel Genetic Immunization for the Development of Antibodies Targeting Conformational and Native Antigens for Diagnostic and Therapy.
Covalab Meddy El Aloui

Meddy El Aloui
CSO
Covalab, France

ImmunResQ: an innovative cytokine- immunotherapy stimulating adaptative and innate immunity for the treatment of immuno-suppressed patients (sepsis)
Transgene Geneviève Inchauspé

Geneviève Inchauspé
Dept. Head, Senior Director
Transgene, France

Covidrogen : Hydrogen Therapy for Covid
CHU Grenoble Philippe Cinquin

Philippe Cinquin
Professor
UGA / CHU Grenoble, France

Validation of SARS-CoV-2 K18-hACE2 infected mice model
Voxcan Emilie Cornaire

Emilie Cornaire
Study Director
Voxcan, France

18h00

End of Day 1

20h00

Cocktail Dinner

Day 2

Tuesday, 16th November 2021

8h30

Welcome coffee

9h00

Keynote lectures

Scientific and economic challenges in antibiotic drug development and access
GARDP Jean-Pierre Paccaud

Jean-Pierre Paccaud
Director of Business Development and Corporate Strategy
GARDP, Switzerland

GlaxoSmithKline Vaccines Rino Rappuoli

Rino Rappuoli
Global Head of Vaccines R&D
GlaxoSmithKline Vaccines, Italy

10h00

Coffee Break - Exhibition Hall - B2B Meetings

10h30

Track 4 : Next-generation of vaccine design

Session 1

Immunity elicited by herpesvirus-vectored vaccines against Newcastle disease and Avian influenza in poultry
CEVA Animal Health Gwenaelle Dauphin

Gwenaelle Dauphin
Coordinator of scientific activities
CEVA Animal Health, France

Understanding the Fate of mRNA Vaccines in vivo and Mechanisms of Early Responses.
Institut Karolinska Karin Loré

Karin Loré
Professor
Institut Karolinska, Sweden

BioNTech Alexander Muik

Alexander Muik
Director Immunomodulators
BioNTech, Germany

Moderna Andrea Carfi

Andrea Carfi
VP & Head of Research for Infectious Disease
Moderna, USA

Track 5 : Leveraging clinical trials data

Session 1

Profiling of the immune responses to SARS-Cov-2 in children
Faculty of medicine of Geneva Arnaud Didierlaurent

Arnaud Didierlaurent
Professor
Faculty of medicine of Geneva, Switzerland

Optimizing clinical trials in an emerging infectious disease crisis
Pasteur Institute Bruno Hoen

Bruno Hoen
Professor, Medical Research Director
Pasteur Institute, France

Helping researchers to make their research on infectious diseases safe and simple
Miltenyi Biotec Shahul Hoen

Shahul Mouhamad
Product Manager
Miltenyi Biotec, France

12h00

Lunch - Poster Presentation - B2B Meetings 5 slots - Exhibition Hall

14h00

Track 4 : Next-generation of vaccine design

Session 2

AI-based data extraction towards e-prediction of vaccine reactogenicity
Sanofi Pasteur Paul Desert

Paul Desert
Head of Non-Clinical Safety
Sanofi Pasteur, France

Sanofi Pasteur Joël Le-Pape

Joël Le-Pape
Data Scientist
Sanofi Pasteur, France

Antibody Responses Elicited by a Single Dose of Ad26.COV2.S and Impact of Booster Dose
Janssen Vaccines Jenny Hendricks

Jenny Hendricks
Head Biomarkers Viral Vaccines
Janssen Vaccines, The Netherlands

Aminopeptidase N targeting as a gut delivery platform for oral subunit vaccines
Ghent University Bert Devriendt

Bert Devriendt
Assistant Professor
Ghent University, Belgium

RNA Synthesis – Tools and tips to Take You From Template to Transcript and from R&D to scale up
New England Biolab Morgane Moreau

Morgane Moreau
Technical Sales Engineer
New England Biolab

Track 5 : Leveraging clinical trials data

Session 1

TREM-1 as therapeutic target for COVID-19 critically ill patients with respiratory support, evaluation of the TREM-1 modulator nangibotide
Inotrem Margarita Salcedo-Magguilli

Margarita Salcedo-Magguilli
Chief Development Officer
Inotrem, France

Impaired type I IFN responses in severe COVID-19 patients
HCL-CIRI Sophie Trouillet-Assant

Sophie Trouillet-Assant
PhD
HCL-CIRI, France

University of Edinburgh Kenneth Baillie

Kenneth Baillie
Snr. Clinical Research Fellow in Anaesthesia & Critical Care
University of Edinburgh, Scotland

16h00

Closing keynote

INSERM Marie-Paul Kieny

Marie-Paul Kieny
Research director
INSERM, France

16h30

Best Poster - Annoucemment of next year edition

16h45

End of congress

ORGANIZERS